Screening for Bladder Cancer

  • Laura-Maria Krabbe
  • Robert S. Svatek
  • Yair LotanEmail author


For screening to be cost-effective a disease has to have sufficient prevalence and there need to be tests that can result in early detection and improved survival. While bladder cancer is the fourth most common cancer in men, overall the incidence of bladder cancer is too low to justify screening in the general population. Risk stratification based on known risk factors such as age, gender, smoking history, or occupational exposures may allow identification of a population with sufficient incidence of disease to justify screening. There will need to be optimization of testing for detection and evidence of improved survival from early diagnosis. There is potential for screening to detect disease prior to muscle invasion, which could result in a survival benefit. The cost implications of screening will also be important to consider.

In this chapter we will review the epidemiology of bladder cancer and risk factors for the disease, highlight previous bladder cancer screening trials, and discuss cost issues associated with screening.


Bladder cancer Screening Urine markers Risk factors Cost-effectiveness 


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. Epub 2013/01/22.PubMedCrossRefGoogle Scholar
  2. 2.
    Larre S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, et al. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol. 2013;63(6):1049–58. Epub 2013/01/15.PubMedCrossRefGoogle Scholar
  3. 3.
    NCI. NCI cancer screening overview. 2007. Accessed 26 Aug 2007.
  4. 4.
    Wilson J, Jungers GE. Principles and practice of screening for disease. Geneva, Switzerland: World Health Organization; 1968. p. 163.Google Scholar
  5. 5.
    Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737–45. Epub 2011/08/19.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 1992;6(1):1–30. Epub 1992/02/01.PubMedGoogle Scholar
  7. 7.
    Vickers AJ, Bennette C, Kibel AS, Black A, Izmirlian G, Stephenson AJ, et al. Who should be included in a clinical trial of screening for bladder cancer? A decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Cancer. 2013;119(1):143–9. Epub 2012/06/28.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366(9486):649–59. Epub 2005/08/23.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol. 2012;30(35):4409–15. Epub 2012/10/24.PubMedCrossRefGoogle Scholar
  10. 10.
    Kishi K, Hirota T, Matsumoto K, Kakizoe T, Murase T, Fujita J. Carcinoma of the bladder: a clinical and pathological analysis of 87 autopsy cases. J Urol. 1981;125(1):36–9. Epub 1981/01/01.PubMedGoogle Scholar
  11. 11.
    Messing EM, Young TB, Hunt VB, Wehbie JM, Rust P. Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer. 1989;64(11):2361–7. Epub 1989/12/01.PubMedCrossRefGoogle Scholar
  12. 12.
    Rodgers M, Nixon J, Hempel S, Aho T, Kelly J, Neal D, et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess. 2006;10(18):iii–iv, xi-259. Epub 2006/05/30.Google Scholar
  13. 13.
    Buteau A, Seideman CA, Svatek RS, Youssef RF, Chakrabarti G, Reed G, et al. What is evaluation of hematuria by primary care physicians: use of electronic medical records to assess practice patterns with intermediate follow-up. Urol Oncol. 2014;32:128–34. Epub 2012/11/17.PubMedCrossRefGoogle Scholar
  14. 14.
    Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61(1):109–18. Discussion 18. Epub 2003/02/01.PubMedCrossRefGoogle Scholar
  15. 15.
    Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293(7):810–6. Epub 2005/02/17.PubMedCrossRefGoogle Scholar
  16. 16.
    Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295(3):299–305. Epub 2006/01/19.PubMedCrossRefGoogle Scholar
  17. 17.
    Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002;168(5):1950–4. Epub 2002/10/24.PubMedCrossRefGoogle Scholar
  18. 18.
    Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol. 2008;179(6):2164–9. Epub 2008/04/22.PubMedCrossRefGoogle Scholar
  19. 19.
    Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B, et al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol. 2005;174(4 Pt 1):1238–41. Epub 2005/09/08.PubMedCrossRefGoogle Scholar
  20. 20.
    Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere WR, Sheinfeld J, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology. 1997;50(3):349–53. Epub 1997/09/25.PubMedCrossRefGoogle Scholar
  21. 21.
    Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem. 1999;45(4):472–7. Epub 1999/04/02.PubMedGoogle Scholar
  22. 22.
    Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 1995;45(3):387–96. Discussion 96–7. Epub 1995/03/01.PubMedCrossRefGoogle Scholar
  23. 23.
    Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006;107(9):2173–9. Epub 2006/10/10.PubMedCrossRefGoogle Scholar
  24. 24.
    Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol. 1992;148(3):788–90. Epub 1992/09/01.PubMedGoogle Scholar
  25. 25.
    Mayfield MP, Whelan P. Bladder tumours detected on screening: results at 7 years. Br J Urol. 1998;82(6):825–8. Epub 1999/01/12.PubMedCrossRefGoogle Scholar
  26. 26.
    Hedelin H, Jonsson K, Salomonsson K, Boman H. Screening for bladder tumours in men aged 60-70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy. Scand J Urol Nephrol. 2006;40(1):26–30. Epub 2006/02/03.PubMedCrossRefGoogle Scholar
  27. 27.
    Roobol MJ, Bangma CH, el Bouazzaoui S, Franken-Raab CG, Zwarthoff EC. Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). Urol Oncol. 2010;28(6):686–90. Epub 2010/11/11.PubMedCrossRefGoogle Scholar
  28. 28.
    van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Can Res. 2005;11(21):7743–8. Epub 2005/11/10.CrossRefGoogle Scholar
  29. 29.
    van Rhijn BW, Lurkin I, Kirkels WJ, van der Kwast TH, Zwarthoff EC. Microsatellite analysis–DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer. 2001;92(4):768–75. Epub 2001/09/11.PubMedCrossRefGoogle Scholar
  30. 30.
    Zuiverloon TC, Beukers W, van der Keur KA, Munoz JR, Bangma CH, Lingsma HF, et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int. 2012;109(6):941–8. Epub 2011/07/16.PubMedCrossRefGoogle Scholar
  31. 31.
    Bangma CH, Loeb S, Busstra M, Zhu X, Bouazzaoui SE, Refos J, et al. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol. 2013;64:41–7. Epub 2013/03/13.PubMedCrossRefGoogle Scholar
  32. 32.
    Welty CJ, Wright JL, Hotaling JM, Bhatti P, Porter MP, White E. Persistence of urothelial carcinoma of the bladder risk among former smokers: Results from a contemporary, prospective cohort study. Urol Oncol. 2014;32:25.e21–5. Epub 2013/03/20.CrossRefGoogle Scholar
  33. 33.
    Kogevinas M, ’tMannetje A, Cordier S, Ranft U, Gonzalez CA, Vineis P, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control CCC. 2003;14(10):907–14. Epub 2004/01/31.PubMedCrossRefGoogle Scholar
  34. 34.
    Wu X, Lin J, Grossman HB, Huang M, Gu J, Etzel CJ, et al. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol. 2007;25(31):4974–81. Epub 2007/11/01.PubMedCrossRefGoogle Scholar
  35. 35.
    Steiner H, Bergmeister M, Verdorfer I, Granig T, Mikuz G, Bartsch G, et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int. 2008;102(3):291–6. Epub 2008/03/14.PubMedCrossRefGoogle Scholar
  36. 36.
    Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol. 2009;182(1):52–7. Discussion 8. Epub 2009/05/20.PubMedCrossRefGoogle Scholar
  37. 37.
    Davies M. Final diagnoses after urinary screening of apparently normal workmen. Proc R Soc Med. 1970;63(3):242. Epub 1970/03/01.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, et al. The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int. 2011;108(4):546–52. Epub 2011/01/13.PubMedCrossRefGoogle Scholar
  39. 39.
    Crosby JH, Allsbrook Jr WC, Koss LG, Bales CE, Witherington R, Schulte PA, et al. Cytologic detection of urothelial cancer and other abnormalities in a cohort of workers exposed to aromatic amines. Acta Cytol. 1991;35(3):263–8. Epub 1991/05/01.PubMedGoogle Scholar
  40. 40.
    Marsh GM, Cassidy LD. The Drake Health Registry Study: findings from fifteen years of continuous bladder cancer screening. Am J Ind Med. 2003;43(2):142–8. Epub 2003/01/24.PubMedCrossRefGoogle Scholar
  41. 41.
    Hemstreet 3rd GP, Yin S, Ma Z, Bonner RB, Bi W, Rao JY, et al. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst. 2001;93(6):427–36. Epub 2001/03/22.PubMedCrossRefGoogle Scholar
  42. 42.
    Ward E, Halperin W, Thun M, Grossman HB, Fink B, Koss L, et al. Screening workers exposed to 4,4′-methylenebis(2-chloroaniline) for bladder cancer by cystoscopy. J Occup Med. 1990;32(9):865–8. Epub 1990/09/01.PubMedCrossRefGoogle Scholar
  43. 43.
    Chen HI, Liou SH, Loh CH, Uang SN, Yu YC, Shih TS. Bladder cancer screening and monitoring of 4,4′-methylenebis(2-chloroaniline) exposure among workers in Taiwan. Urology. 2005;66(2):305–10. Epub 2005/08/16.PubMedCrossRefGoogle Scholar
  44. 44.
    Giberti C, Gallo F, Schenone M, Genova A. Early results of urothelial carcinoma screening in a risk population of coke workers: urothelial carcinoma among coke workers. Biomed Environ Sci BES. 2010;23(4):300–4. Epub 2010/10/12.CrossRefGoogle Scholar
  45. 45.
    Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, et al. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. Eur Urol. 2011;59(6):1026–31. Epub 2011/04/05.PubMedCrossRefGoogle Scholar
  46. 46.
    Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–10. Epub 2011/06/07.PubMedCrossRefGoogle Scholar
  47. 47.
    Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, et al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol. 2013;63(2):379–85. Epub 2012/08/14.PubMedCrossRefGoogle Scholar
  48. 48.
    Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117–28. Epub 2011/01/14.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Redaelli A, Cranor CW, Okano GJ, Reese PR. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics. 2003;21(17):1213–38. Epub 2004/02/28.PubMedCrossRefGoogle Scholar
  50. 50.
    Krahn MD, Coombs A, Levy IG. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen. CMAJ Can Med Assoc J. 1999;160(1):49–57. Epub 1999/02/06.Google Scholar
  51. 51.
    Lotan Y, Svatek RS, Malats N. Screening for bladder cancer: a perspective. World J Urol. 2008;26(1):13–8. Epub 2007/11/22.PubMedCrossRefGoogle Scholar
  52. 52.
    Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer. 2006;107(5):982–90. Epub 2006/07/25.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Laura-Maria Krabbe
    • 1
    • 2
  • Robert S. Svatek
    • 3
  • Yair Lotan
    • 1
    Email author
  1. 1.Department of UrologyUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.Department of UrologyUniversity of Muenster Medical CenterMuensterGermany
  3. 3.Department of UrologyUniversity of Texas Health Science Center San AntonioSan AntonioUSA

Personalised recommendations